Format
Sort by

Send to

Choose Destination

Selected items

Items: 20

1.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.

Ann Intern Med. 2011 May 3;154(9):573-82. doi: 10.7326/0003-4819-154-9-201105030-00002.

2.

Omalizumab: clinical use for the management of asthma.

Thomson NC, Chaudhuri R.

Clin Med Insights Circ Respir Pulm Med. 2012;6:27-40. doi: 10.4137/CCRPM.S7793.

3.

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C.

J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1. doi: 10.1016/j.jaci.2012.07.047.

PMID:
23021878
4.

Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.

Chipps BE, Figliomeni M, Spector S.

Allergy Asthma Proc. 2012 Sep-Oct;33(5):377-85. doi: 10.2500/aap.2012.33.3599.

PMID:
23026179
5.

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.

Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA.

N Engl J Med. 2011 Mar 17;364(11):1005-15. doi: 10.1056/NEJMoa1009705.

6.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
7.

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W.

Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. doi: 10.1164/rccm.201208-1414OC.

PMID:
23471469
8.

Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.

Eisner MD, Zazzali JL, Miller MK, Bradley MS, Schatz M.

J Asthma. 2012 Aug;49(6):642-8. doi: 10.3109/02770903.2012.690477.

PMID:
22793527
9.

Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.

Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, Molimard M, Abenhaim L; Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group..

Chest. 2013 Feb 1;143(2):398-405.

PMID:
23505637
10.

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.

Allergy. 2005 Mar;60(3):309-16.

11.

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma.

Brodlie M, McKean MC, Moss S, Spencer DA.

Arch Dis Child. 2012 Jul;97(7):604-9. doi: 10.1136/archdischild-2011-301570.

PMID:
22685051
12.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators..

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297.

PMID:
22356355
13.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N.

J Allergy Clin Immunol. 2001 Aug;108(2):184-90.

PMID:
11496232
14.

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.

Respir Med. 2012 Nov;106(11):1494-500. doi: 10.1016/j.rmed.2012.07.010.

15.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.

Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Ann Allergy Asthma Immunol. 2012 Jul;109(1):59-64. doi: 10.1016/j.anai.2012.04.015.

PMID:
22727159
16.

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.

Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF.

J Allergy Clin Immunol. 2009 Dec;124(6):1210-6. doi: 10.1016/j.jaci.2009.09.021.

PMID:
19910033
17.

Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.

Storms W, Bowdish MS, Farrar JR.

Allergy Asthma Proc. 2012 Mar-Apr;33(2):172-7. doi: 10.2500/aap.2012.33.3527.

PMID:
22525394
18.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
19.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.

Walker S, Burch J, McKenna C, Wright K, Griffin S, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:13-21. doi: 10.3310/hta15suppl1/02. Review.

20.

Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.

de Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, Zamarro S, Picado C; Spanish Registry..

J Asthma. 2013 Apr;50(3):296-301. doi: 10.3109/02770903.2012.757780. Erratum in: J Asthma. 2013 Jun;50(5):537-9.

PMID:
23350994
Items per page

Supplemental Content

Support Center